FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1567-1569 December 7, 1995 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Kamel, O. W. Related Article by Tugwell, P. Related Article by Mason, J. W.

To the Editor: Tugwell et al. (July 20 issue)¹ found that "patients with severe rheumatoid arthritis and only partial responses to methotrexate had clinically important improvement after combination therapy with cyclosporine and methotrexate." We are concerned about the manner in which the cyclosporine doses were adjusted. No mention of the patients' serum cyclosporine levels was made. Determination of serum cyclosporine levels might have allowed a better understanding of the results with respect to therapeutic serum ranges of this medication.

The authors state that people with rheumatoid arthritis "have a risk of cancer 20 to 30 times higher than people in . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.